Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx

→ San Diego-based Imprimis has set up a new subsidiary to pursue the development of new drugs for eye diseases. And the company has tapped Kamran Hosseini to run the operation — Surface Pharmaceuticals — as the CEO.

The Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation are helping fund a new combination therapy for Alzheimer’s by Amylyx Pharmaceuticals. Their $1.85 million grant will support a small Phase II study with 50 patients, who will be treated with AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid.

→ Framingham, MA-based Alzheon says that it has gained the FDA’s fast track designation for the Alzheimer’s drug ALZ-801.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->